ADARx Pharmaceuticals Inc. (ADRX)
NASDAQ: ADRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ADRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.85B
- EPS (TTM)
- -$1.16
- Dividend yield
- None
- 52-week range
- 17.20 – 23.21
- Day range
- 17.20 – 18.70
- Volume / Avg
- 705.60K / 1.42M
- Beta
- —
- Shares outstanding
- 106.80M
52-week range
ADRX stock today
ADARx Pharmaceuticals (ADRX) closed at $17.33 on Oct 7, down 6.73% (-$1.25), versus the S&P 500's 0.22% decline. Trading was light, with 705.60K shares changing hands, about 50% of the average daily volume. Shares are 25.3% below their 52-week high of $23.21, set on Sep 25, 2026 and 0.8% above the 52-week low of $17.20, near the bottom of the past year's range.
ADARx Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.16), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About ADARx Pharmaceuticals
Company profileADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Zhen Li Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 100
- IPO year
- 2026
- Website
- adarx.com
ADARx Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SRPTSarepta Therapeutics Inc. | 17.50 | +1.10% | $1.85B | vs ADRX |
| XERSXeris Biopharma Holdings Inc. | 10.11 | +0.40% | $1.84B | vs ADRX |
| ZBIOZenas BioPharma Inc. | 28.18 | +4.60% | $1.84B | vs ADRX |
| TRVITrevi Therapeutics Inc. | 13.14 | -0.30% | $1.87B | vs ADRX |
| PVLAPalvella Therapeutics Inc. | 130.59 | +2.02% | $1.88B | vs ADRX |
| XNCRXencor Inc. | 24.26 | -0.41% | $1.80B | vs ADRX |
| AGIOAgios Pharmaceuticals Inc. | 31.79 | +0.22% | $1.90B | vs ADRX |
| GPCRStructure Therapeutics Inc. ADR | 26.68 | -2.88% | $1.90B | vs ADRX |
Indexes, lists and sector
ADARx Pharmaceuticals stock FAQ
What is ADARx Pharmaceuticals's stock price today?
ADRX last traded at $17.33 as of Oct 7, 4:00 PM EDT, down 6.73% on the day. Prices are delayed at least 15 minutes.
Who is ADARx Pharmaceuticals's CEO?
Dr. Zhen Li Ph.D. is the chief executive officer of ADARx Pharmaceuticals Inc., which has about 100 employees.
What is the ADRX 52-week high?
The 52-week high for ADRX is $23.21 and the 52-week low is $17.20. The stock is currently 25.3% below its high.